NCT03224702View on ClinicalTrials.gov

First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 4, 2017

Primary Completion Date

August 6, 2018

Study Completion Date

August 6, 2018

Conditions
Healthy
Interventions
DRUG

M6495

Subjects will receive M6495 on Day 1

DRUG

Placebo

Subjects will receive placebo matched to M6495 on Day 1

Trial Locations (1)

DK-2400

DanTrials ApS c/o Bispebjerg Hospital, Copenhagen

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03224702 - First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers | Biotech Hunter | Biotech Hunter